PNC-27
PNC-27 is a synthetic anticancer peptide that selectively targets and destroys cancer cells by binding to HDM-2, an oncoprotein expressed on cancer cell membranes but absent on healthy cells. It forms transmembrane pores causing necrosis rather than apoptosis, reducing metastasis risk. Effective against leukemia, breast, pancreatic, colorectal, and ovarian cancers with minimal impact on healthy tissue. Available as lyophilized powder.
Available SKUs
| Model | Specification | MOQ |
|---|---|---|
| pnc27-5 | 5ml | 1 vial |
| pnc27-10 | 10ml | 1 vial |
| pnc27-20 | 20ml | 1 vial |
Product Overview
PNC-27 is a chimeric p53-penetratin peptide that targets the HDM-2 protein found on cancer cell membranes. Its selectivity is based on the critical observation that HDM-2 is highly expressed on cancer cell membranes but is very low or undetectable on normal, healthy cells. This creates a precise targeting mechanism that distinguishes it from conventional chemotherapy.
Mechanism of Action
PNC-27 binds to HDM-2 proteins on cancer cell membrane surfaces, inducing transmembrane pore formation. This pore formation disrupts membrane integrity, causing water influx and cell bursting (necrosis). Additionally, PNC-27 damages cancer cell mitochondria, further compromising cellular viability. This dual action — membranolysis plus mitochondrial damage — delivers comprehensive cancer cell destruction.
Key Benefits
High Cancer Cell Selectivity — Binds exclusively to HDM-2 on cancer cell membranes, leaving healthy cells unharmed. Provides targeted therapy without the systemic toxicity of conventional chemotherapy.
Broad-Spectrum Efficacy — Demonstrated effectiveness against multiple cancer types including acute myeloid leukemia, breast cancer, pancreatic cancer, colorectal cancer, ovarian cystadenocarcinoma, and melanoma.
Necrosis-Based Mechanism — Induces necrosis rather than apoptosis, which may reduce the risk of tumor cell fragments entering the bloodstream and causing metastatic spread.
Mitochondrial Disruption — Damages cancer cell mitochondria as an additional mechanism of action, providing a multi-layered attack on cancer cell viability.
References
- Sarafraz-Yazdi E, et al. PNC-27 binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis. *Biomedicines.* 2022;10(5):945.
- Ghaly G, et al. Anti-cancer peptides: status and future prospects. *Molecules.* 2023;28(3):1148.
- Bowne WB, et al. Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer. *Cancer Therapy.* 2007;5B:331.
| Molecular Formula | Chimeric peptide |
|---|---|
| Molecular Weight | ~3500 g/mol |
| Sequence/Composition | p53-penetratin chimeric peptide |
| Amino Acids | ~32 |
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC |
| Storage | -20°C desiccated |
Need OEM or a Custom Configuration?
We offer custom synthesis, modifications, and OEM services. Share your requirements including sequence, purity, quantity, and any special needs—our team will provide a detailed quote.